Skip to main content
Clinical Trials/IRCT20080728001031N35
IRCT20080728001031N35
Completed
Phase 1

Safety of intradiscal injection of nucleus pulposus derived stromal cells in regeneration of human degenerated lumbar disc in patients with chronic low back pain

Royan Institute0 sites5 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Royan Institute
Enrollment
5
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 65 years
  • Of both sexes
  • Degenerative intervertebral disc in one or two lumbar intervertebral discs with pain that has not responded to previous supportive therapies, including the use of conventional analgesics or physiotherapy within the last 6 months.
  • The fibrous ring is able to hold the injected cell based on the discography performed. This means that stage of the disease must be 2,3 or 4 and stage 5 cannot be included in the study.
  • Reduction of intervertebral disc height by 50% or more based on radiography.
  • Do not have a vertebral infection.
  • Have no uncontrolled chronic underlying disease that is prohibited for treatment.
  • Have no uncontrolled chronic underlying disease that is prohibited for treatment.
  • Do not be pregnant or breastfeeding women.
  • Not positive and transmissible viral infection.

Exclusion Criteria

  • infection signs or positive serology for HIV, hepatitis and syphilis
  • allergy to gentanicin, or to bovine, cattle or horse serum
  • congenital or acquired disease leading to spine deformities that may upset cell application
  • spinal segmental instability, spinal canal stenos, isthmus pathology, and other conditions that may compromise the study
  • modic 3 changes on MRI images
  • overweight with body mass index greater than 30\.5
  • immunosuppression
  • participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study
  • other conditions that may, according to medical criteria, discourage participation in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials